# Entecavir

## Baraclude 0.5mg

| 藥物代碼 | OBAR |
| :--- | :--- |
| 適應症 | Treatment of chronic HBV infection in adults with evidence of active viral replication & either evidence of persistent elevations in serum aminotransferases \(ALT or AST\) or histologically active disease. |
| 副作用 | Diarrhea, dyspepsia, nausea, vomiting. Fatigue. Headache, dizziness, somnolence. Insomnia.Gastrointestinal: Nausea \(all grades, 3% or greater; grade 2 to 4, less than 1% \)Neurologic: Dizziness \(all grades, 3% or greater; grade 2 to 4, less than 1% \), Headache \(all grades, 3% or greater; grade 2 to 4, 2% to 4% \)Other: Fatigue \(all grades, 3% or greater; grade 2 to 4, 1% to 3% \) |
| 禁忌 | Patients who previously demonstrated hypersensitivity to entecavir or any of the components of Baraclude. |
| 懷孕用藥危分級 | 除非治療上需要 |
| 孕期用藥建議 | Compatible - maternal benefit &gt;&gt; embryo-fetal risk |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Probably Compatible 無\(很少\)資料 - 可使用 |
| 附帶說明 | HIV: \[U.S. Boxed Warning\]: May cause the development of HIV resistance in chronic hepatitis B patients with unrecognized or untreated HIV infection. Determine HIV status prior to initiating treatment with entecavir. Not recommended for HIV/HBV coinfected patients unless also receiving highly active antiretroviral therapy \(HAART\). |
| 注射劑給藥建議途徑 | N/A |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

## 1mg BARACLUDE

| 藥物代碼 | OBAR1 |
| :--- | :--- |
| 適應症 | Treatment of chronic hepatitis B virus \(HBV\) infection in adults and pediatric patients 2 years and older with evidence of active viral replication and either evidence of persistent transaminase elevations or histologically-active disease. Note: In adults, indication is based on data in patients with compensated and decompensated liver disease; in children, indication is based on data in patients with compensated liver disease. |
| 副作用 | Diarrhea, dyspepsia, nausea, vomiting. Fatigue. Headache, dizziness, somnolence. Insomnia. |
| 禁忌 | Hypersensitivity to entecavir or any component of the formulation |
| 懷孕用藥危分級 | 除非治療上需要 |
| 孕期用藥建議 | Compatible - maternal benefit &gt;&gt; embryo-fetal risk |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Probably Compatible 無\(很少\)資料 - 可使用 |
| 附帶說明 | upper table \(according to up to date of Pregnancy Risk Factor and Lactation \) HIV: \[U.S. Boxed Warning\]: May cause the development of HIV resistance in chronic hepatitis B patients with unrecognized or untreated HIV infection. Determine HIV status prior to initiating treatment with entecavir. Not recommended for HIV/HBV coinfected patients unless also receiving highly active antiretroviral therapy \(HAART\). |
| 注射劑給藥建議途徑 | N/A |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

